

I hereby certify that this correspondence is being facsimile transmitted to the U.S. Patent and Trademark Office, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, Mail Stop: Amendment to Facsimile No. 571-273-8300 on the date shown below:

On December 21, 2005

By Joanne R. Petithory
Joanne R. Petithory

Attorney Docket No. 0169.410US

RECEIVED
CENTRAL FAX CENTER

DEC 21 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Juha Punnonen *et al.*

Application No: 10/032,214

Filed: December 20, 2001

For: NOVEL CO-STIMULATORY
MOLECULES

Examiner: Ilia I. Ouspenski

Art Unit: 1644

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT UNDER 37 CFR
§1.97 and §1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450
Mail Stop: Amendment

Sir:

The references cited on attached form PTO/SB/08A-B are being called to the attention of the Examiner. These references were made of record in parent application USSN 09/888,324. Because copies of these references were provided in said parent application, Applicants are not enclosing additional copies herewith, but respectfully request that the Examiner utilize the copies provided in the parent application. If the Examiner would like fresh copies of the references, Applicants will be pleased to provide them again. It is respectfully requested that the cited information be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

12/22/2005 HDEHES1 00000018 500990 10032214

01 FC:1806 180.00 DA

Application No. 10/032,214

Page 2

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

As this supplemental Information Disclosure Statement is being submitted after the mailing of the First Office Action, but before the mailing date of any final action or Notice of Allowance, Applicants are submitting herewith the fee specified under 37 CFR § 1.17(p). The Commissioner is authorized to deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account No. 50-0990.

Respectfully submitted,

By: Joanne R. Petithory
Joanne R. Petithory, Ph.D.
Reg. No. 42,995

Maxygen, Inc.
Intellectual Property Department
515 Galveston Drive
Redwood City, California 94063
Telephone: (650) 298-5300
Facsimile: (650) 298-5446
Customer No. 30560

(Modified) PTO/SB/08A-B (10-96)
Approved for use through 10/31/99. OMB 0651-0031

Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Complete if Known	
	Application Number	10/032,214
	Filing Date	December 20, 2001
	First Named Inventor	Juha Punnonen, et al.
	Group Art Unit	1644
	Examiner Name	Iliia I. Ouspenski
	Attorney Docket Number	0169.410US

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			
	1	5,718,883		Harlan et al.	02-17-1998	
	2	5,738,852		Robinson et al.	04-14-1998	
	3	5,858,776		Ostrand-Rosenberg et al.	01-12-1999	
	4	6,045,802		Schlom et al.	04-04-2000	
	5	6,149,905		Ostrand-Rosenberg et al.	11-21-2000	

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				
	6	WO	94/24267		Robinson, William S.	10-27-1994		
	7	WO	95/23859		Brigham/Women's Hosp.; Dana-Farber Cancer Inst.	09-08-1995		
	8	WO	95/03408		Dana-Farber Cancer Inst.	02-02-1995		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s).	T
	9	He, X-S. et al., "Costimulatory protein B7-1 enhances the cytotoxic T cell response and antibody response to hepatitis B surface antigen," Proc. Natl. Acad. Sci. USA 93:7274-7278 (1996)	
	10	Kuchroo, V.K. et al., "B7-1 and B7-2 Costimulatory Molecules Activate Differentially the Th1/Th2 Developmental Pathways: Application to Autoimmune Disease Therapy," Cell 80:707-718 (1995)	
	11	Metzler, W., et al., "Solution Structure of Human CTLA-4 and Delineation of a CD80/CD86 Binding Site Conserved in CD28," Nature Structural Biology 4(7):527-531 (July 1997)	
	12	Rennert, P. et al., "The IgV domain of human B7-2 (CD86) is sufficient to co-stimulate T lymphocytes and induce cytokine secretion," International Immunology 9(6):805-813 (1997)	
	13	Wu, Y., "CTLA-4-B7 Interaction is Sufficient to Costimulate T Cell Clonal Expansion," J. Exp. Med. 185(7):1327-1335 (1997)	
	14	Doty, R. et al., "Subcellular localization of CD80 receptors is dependent on an intact cytoplasmic tail and is required for CD28-dependent T cell costimulation," Journal of Immunology 157:3270-3279 (1996)	
	15	Linsley, P.S. et al., "Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors," Immunity 1:793-801 (December 1994)	
	16	Linsley, P.S. et al., "Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation," J. Exp. Med. 173:721-730 (March 1991)	
	17	Sturmhoefel, K., "Potent activity of soluble B7-1gG fusion proteins in therapy of established tumors and as vaccine adjuvant," Cancer Research 59:4964-4972 (October 1999)	
	18	Swiniarski, H. et al., "Immune response enhancement by <i>in vivo</i> administration of B7.21g, a soluble costimulatory protein," Clinical Immunology 92(3):235-245 (1999)	
Examiner Signature			Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.